Trial Profile
Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 27 Feb 2023 Status changed from active, no longer recruiting to completed.
- 01 May 2019 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
- 01 May 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2019.